0 7 1001 Doctors NNS
8 12 1002 have VBP
13 22 1003 developed VBN
23 24 1004 a DT
25 28 1005 new JJ
29 35 1006 device NN
36 38 1007 to TO
39 46 1008 measure NN
47 53 1009 cancer NN
54 59 1010 cells NNS
60 64 1011 that WDT
65 70 1012 break VBP
71 74 1013 off IN
75 79 1014 from IN
80 84 1015 lung NN
85 91 1016 tumors NNS
92 95 1017 and CC
96 102 1018 travel NN
103 110 1019 through IN
111 114 1020 the DT
115 120 1021 blood NN
120 121 1022 . .
122 124 2001 It PRP
125 128 2002 can MD
129 133 2003 also RB
134 143 2004 determine VB
144 148 2005 when WRB
149 152 2006 the DT
153 159 2007 cancer NN
160 165 2008 cells NNS
166 172 2009 become VBP
173 182 2010 resistant JJ
183 185 2011 to TO
186 190 2012 drug NN
191 201 2013 treatments NNS
201 202 2014 . .
203 206 3001 The DT
207 217 3002 technology NN
218 221 3003 was VBD
222 231 3004 developed VBN
232 234 3005 at IN
235 248 3006 Massachusetts NNP
249 256 3007 General NNP
257 265 3008 Hospital NNP
266 268 3009 in IN
269 275 3010 Boston NNP
275 276 3011 . .
278 279 4001 A NNP
280 288 4002 clinical JJ
289 294 4003 trial NN
295 300 4004 using VBG
301 304 4005 the DT
305 311 4006 device NN
312 315 4007 was VBD
316 325 4008 published VBN
326 328 4009 in IN
329 332 4010 the DT
333 336 4011 New NNP
337 344 4012 England NNP
345 352 4013 Journal NNP
353 355 4014 of IN
356 364 4015 Medicine NNP
364 365 4016 . .
366 369 5001 VOA NNP
369 371 5002 's POS
372 379 5003 Deborah NNP
380 385 5004 Block NNP
386 389 5005 has VBZ
390 394 5006 more JJR
394 395 5007 . .
